Effectiveness of the Cytokine Hemadsorption on Sepsis

NCT05057455 | Completed

• 1 other identifier: BIRUNI 2
• Study Type: observational
• Target: 39
• Locations: 1 country
• Sites: 1

Brief Summary

In this prospective study, we aimed to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.

Conditions

Interleukin-6

Outcome Measures

Primary Outcomes (1)

• IL-6

  levels of IL-6

  1 YEARS

Study Arms (1)

ICU patients diagnosed with sepsis or septic shock

compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.

Procedure: cytokine hemadsorption

Interventions

cytokine hemadsorption PROCEDURE

the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.

ICU patients diagnosed with sepsis or septic shock

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

In this one-centered study, we prospectively analyzed the outcomes and laboratory findings of 39 patients diagnosed with sepsis from 01 Jan 2020 to 30 December 2020 hospitalized in ICU.

You may qualify if:

• the patients were the available data of clinical and laboratory diagnosis of sepsis and septic shock
• detection of gram-negative bacterial agent in blood or sputum culture.
• patients who had the shock symptoms such as hypotension, tachycardia or fever during the course of sepsis.

You may not qualify if:

• had uncontrolled hemorrhage,
• diagnosed with cardiac failure at stage 4 or renal failure at stage 4 or hepatic liver failure at stage 4
• cancer at the end stage or admitted with acute coronary syndrome.

Sponsors & Collaborators

• Biruni University: lead

Study Sites (1)

Ilke Kupeli

Istanbul, 34250, Turkey (Türkiye)

Location

Related Publications (4)

• Bahar I, Oksuz H, Senoglu N, Demirkiran H, Aydogan M, Tomak Y, Comez M, Bayrakci S, Gonullu E, Berktas M. Compliance With the Surviving Sepsis Campaign Bundle: A Multicenter Study From Turkey. Cureus. 2021 May 12;13(5):e14989. doi: 10.7759/cureus.14989.

  PMID: 34131534 BACKGROUND

• Houschyar KS, Pyles MN, Rein S, Nietzschmann I, Duscher D, Maan ZN, Weissenberg K, Philipps HM, Strauss C, Reichelt B, Siemers F. Continuous hemoadsorption with a cytokine adsorber during sepsis - a review of the literature. Int J Artif Organs. 2017 May 29;40(5):205-211. doi: 10.5301/ijao.5000591. Epub 2017 May 19.

  PMID: 28525674 RESULT

• Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ;Cytokine Storm' in COVID-19. J Infect. 2020 Jun;80(6):607-613. doi: 10.1016/j.jinf.2020.03.037. Epub 2020 Apr 10.

  PMID: 32283152 RESULT

• Bonavia A, Groff A, Karamchandani K, Singbartl K. Clinical Utility of Extracorporeal Cytokine Hemoadsorption Therapy: A Literature Review. Blood Purif. 2018;46(4):337-349. doi: 10.1159/000492379. Epub 2018 Sep 3.

  PMID: 30176653 RESULT

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: investigator

Study Record Dates

• First Submitted: September 16, 2021
• First Posted: September 27, 2021
• Study Start: January 1, 2020
• Primary Completion: December 30, 2020
• Study Completion: February 15, 2021
• Last Updated: September 27, 2021

Record last verified: 2021-09

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)